Recent advances in the treatment of systemic fungal infections.
Systemic fungal infections are life-threatening diseases that are occurring with increasing frequency, especially in immunocompromised patients. Advances in the treatment of systemic fungal infections have been achieved through better understanding of two classic antifungal drugs, amphotericin B and flucytosine, and through the recent development of several antifungal azole derivatives. The purpose of this paper is to review the recent advances in pharmacology, toxicology, formulation and clinical trials of antifungal agents for the treatment of systemic mycoses.
Walsh
T J
TJ
Pediatric Branch, National Cancer Institute, Bethesda, Maryland.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D015725:Fluconazole; D005437:Flucytosine / Q000627:therapeutic use; D006801:Humans; D017964:Itraconazole; D007654:Ketoconazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D008825:Miconazole / Q000627:therapeutic use; D009181:Mycoses / Q000188:drug therapy* / Q000209:etiology; D014230:Triazoles / Q000627:therapeutic use
D000935:Antifungal Agents; D014230:Triazoles; D017964:Itraconazole; D008825:Miconazole; D000666:Amphotericin B; D015725:Fluconazole; D005437:Flucytosine; D007654:Ketoconazole